7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 22, 2011, Pages 6687-6692

  Pierre, Fabrice ^a   Stefan, Eric ^a   Nédellec, Anne Sophie ^a   Chevrel, Marie Claire ^a   Regan, Collin F ^a   Siddiqui Jain, Adam ^a   MacAlino, Diwata ^a   Streiner, Nicole ^a   Drygin, Denis ^a   Haddach, Mustapha ^a   O'Brien, Sean E ^a   Anderes, Kenna ^a   Ryckman, David M ^a  

^a Cylene Pharmaceuticals   (United States)

Author keywords

AML; Cancer; Kinase inhibitor; Leukemia; Pim

Indexed keywords

7 (4H 1,2,4 TRIAZOL 3 YL)BENZO[C][2,6]NAPHTHYRIDINE; PROTEIN BAD; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; ENZYME INHIBITION; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LEUKEMIA; NAPHTHYRIDINES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; TRIAZOLES;

EID: 80054761333     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.059     Document Type: Article

References (42)

1. M.C. Nawijn, A. Alendar, and A. Berns Nat. Rev. Cancer 11 2010 23
2. R. Amaravadi, and C.B. Thompson J.Clin. Invest. 115 2005 2618
3. T.L. Aho, J. Sandholm, K.J. Peltota, H.P. Mankonen, M. Lilly, and P.J. Koskinen FEBS Lett. 571 2004 43
4. A. Macdonald, D.G. Campbell, R. Toth, H. McLauchlan, C.J. Hastie, and J.S. Arthur BMC Cell Biol. 7 2006 1
5. B. Yan, M. Zemskova, S. Holder, V. Chin, A. Kraft, P.J. Koskinen, and M. Lilly J. Biol. Chem. 278 2003 45358
6. K.T. Kim, M. Levis, and D. Small Br. J. Haematol. 134 2006 500
7. K.T. Kim, K. Baird, J.Y. Ahn, P. Meltzer, M. Lilly, M. Levis, and D. Small Blood 105 2005 1759
8. T. Morwick Expert Opin. Ther. Pat. 2010 2010 193
9. J.X. Ren, L.L. Li, R.L. Zheng, H.Z. Xie, Z.X. Cao, S. Feng, Y.L. Pan, X. Chen, Y.Q. Wei, and S.Y. Yang J. Chem. Inf. Model. 51 2011 1364
10. Y. Xiang, B. Hirth, G. Asmussen, H.P. Biemann, K.A. Bishop, A. Good, M. Fitzgerald, T. Gladysheva, A. Jain, K. Jancsics, J. Liu, M. Metz, A. Papoulis, R. Skerlj, J.D. Stepp, and R.R. Wei Bioorg. Med. Chem. Lett. 21 2011 3050
11. C. Blanco-Aparicio, A.M. Collazo, J. Oyarzabal, J.F. Leal, M.I. Albaran, F.R. Lima, B. Pequeno, N. Ajenjo, M. Becerra, P. Alfonso, M.I. Reymundo, I. Palacios, G. Mateos, H. Quinones, A. Corrionero, A. Carnero, P. Pevarello, A.R. Lopez, J. Fominaya, J. Pastor, and J.R. Bischoff Cancer Lett. 300 2010 145
12. M. Lopez-Ramos, R. Prudent, V. Moucadel, C.F. Sautel, C. Barette, L. Lafanechere, L. Mouawad, D. Grierson, F. Schmidt, J.C. Florent, P. Filippakopoulos, A.N. Bullock, S. Knapp, J.B. Reiser, and C. Cochet Faseb J. 24 2010 3171
13. A.C. Pierce, M. Jacobs, and C. Stuver-Moody J. Med. Chem. 52 2008 1972
14. V. Pogacic, A.N. Bullock, O. Fedorov, P. Filippakopoulos, C. Gasser, S. Biondi, S. Meyer-Monard, S. Knapp, and J. Schwaller Cancer Res. 67 2007 6916
15. R. Grey, A.C. Pierce, G.W. Bemis, M.D. Jacobs, C.S. Moody, R. Jajoo, N. Mohal, and J. Green Bioorg. Med. Chem. Lett. 19 2009 3019
16. A.N. Bullock, J.E. Debreczeni, O.Y. Fedorov, A. Nelson, B.D. Marsden, and S. Knapp J. Med. Chem. 48 2005 7604
17. S. Holder, M. Zemskova, C. Zhang, M. Tabrizizad, R. Bremer, J.W. Neidigh, and M.B. Lilly Mol. Cancer Ther. 6 2007 163
18. I.W. Cheney, S. Yan, T. Appleby, H. Walker, T. Vo, N. Yao, R. Hamatake, Z. Hong, and J.Z. Wu Bioorg. Med. Chem. Lett. 17 2007 1679
19. Z. Xia, C. Knaak, J. Ma, Z.M. Beharry, C. McInnes, W. Wang, A.S. Kraft, and C.D. Smith J. Med. Chem. 52 2009 74
20. Z.F. Tao, L.A. Hasvold, J.D. Leverson, E.K. Han, R. Guan, E.F. Johnson, V.S. Stoll, K.D. Stewart, G. Stamper, N. Soni, J.J. Bouska, Y. Luo, T.J. Sowin, N.H. Lin, V.S. Giranda, S.H. Rosenberg, and T.D. Penning J. Med. Chem. 52 2009 6621
21. K. Qian, L. Wang, C.L. Cywin, B.T. Farmer, E. Hickey, C. Homon, S. Jakes, M.A. Kashem, G. Lee, S. Leonard, J. Li, R. Magboo, W. Mao, E. Pack, C. Peng, A. Prokopowicz, M. Welzel, J. Wolak, and T. Morwick J. Med. Chem. 52 2009 1814
22. R. Akue-Gedu, L. Nauton, V. Thery, J. Bain, P. Cohen, F. Anizon, and P. Moreau Bioorg. Med. Chem. 18 2010 6865
23. Y. Tong, K.D. Stewart, S. Thomas, M. Przytulinska, E.F. Johnson, V. Klinghofer, J. Leverson, O. McCall, N.B. Soni, Y. Luo, N.H. Lin, T.J. Sowin, V.L. Giranda, and T.D. Penning Bioorg. Med. Chem. Lett. 18 2008 5206
24. M. Adam, V. Pogacic, M. Bendit, R. Chappuis, M.C. Nawijn, J. Duyster, C.J. Fox, C.B. Thompson, J. Cools, and J. Schwaller Cancer Res. 66 2006 3828
25. L.S. Chen, S. Redkar, D. Bearss, W.G. Wierda, and V. Gandhi Blood 114 2009 4150
26. Phase I of SGI-1776 was discontinued in Nov. 2010 (http://www.supergen. com/investors/pressrelease.html?pressReleaseId=905).
27. M.A. Pagano, J. Bain, Z. Kazimierczuk, S. Sarno, M. Ruzzene, G. Di Maira, M. Elliott, A. Orzeszko, G. Cozza, F. Meggio, and L.A. Pinna Biochem. J. 415 2008 353
28. F. Pierre, P.C. Chua, S.E. O'Brien, A. Siddiqui-Jain, P. Bourbon, M. Haddach, J. Michaux, J. Nagasawa, M.K. Schwaebe, E. Stefan, A. Vialettes, J.P. Whitten, T.K. Chen, L. Darjania, R. Stansfield, K. Anderes, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. Streiner, K. Trent, W.G. Rice, and D.M. Ryckman J. Med. Chem. 54 2011 635
29. A. Siddiqui-Jain, D. Drygin, N. Streiner, P.C. Chua, F. Pierre, S.E. O'Brien, J. Bliesath, M. Omori, C. Ho, C. Proffitt, M.K. Schwaebe, D.M. Ryckman, W.G. Rice, and K. Anderes Cancer Res. 70 2010 10288
30. R. Battistutta, G. Cozza, F. Pierre, E. Papinutto, G. Lolli, S. Sarno, S.E. O'Brien, A. Siddiqui-Jain, M. Haddach, K. Anderes, D.M. Ryckman, F. Meggio, and L.A. Pinna Biochemistry 50 2011 8478
31. Galan, A. A.; CHen, J.; Du, H.; Forsyth, T.; Huynh, T. P.; Johnson, H. W. B.; Kearney, P.; Leahy, J. W.; Lee, M. S.; Mann, G.; Ridgway, B. H.; Takeuchi, C. S.; Zhou, P. Patent application WO2008/042282A2, 2008, 142.
32. Andrews, D. M.; Jones, C. D.; Simpson, I.; Ward, R. A. Patent application WO2009/024824A1, 2009, 87.
33. Bold, G.; Furet, P.; Guagnano, V. Patent application WO2007/71752, 2007, 84.
34. Jones, R. M.; Lehmann, J.; Wong, A. S. T.; Hurst, D.; Y.J., S. Patent application US2006/1555128 A1, 2006, 52.
35. All final compounds were characterized by LCMS and found to be ≥95% pure, except for compounds 15a, 14l and 3 (90-93% purity). Selected compounds were characterized by NMR.
36. 50 values were derived from eight concentrations of test inhibitors.
37. G.A. Patani, and E.J. LaVoie Chem. Rev. 96 1996 3147
38. 50 values were derived from ten concentrations of test inhibitors.
39. Y.Y. Li, B.K. Popivanova, Y. Nagai, H. Ishikura, C. Fujii, and N. Mukaida Cancer Res. 66 2006 6741
40. H.C. Zheng, K. Tsuneyama, H. Takahashi, S. Miwa, T. Sugiyama, B.K. Popivanova, C. Fujii, K. Nomoto, N. Mukaida, and Y. Takano J. Cancer Res. Clin. Oncol. 134 2008 481
41. B.K. Popivanova, Y.Y. Li, H. Zheng, K. Omura, C. Fujii, K. Tsuneyama, and N. Mukaida Cancer Sci. 98 2007 321
42. The AML cells MV-4-11 were treated with 8 different concentrations of the tested compounds for 4 h. Samples were lysed under non-denaturing conditions and levels of Phospho-Bad (Ser112) and Phospho-FLT3 (Tyr591) were quantified using a commercial ELISA kit from Cell Signaling, according to the manufacturer's protocols. Cell proliferation inhibition was determined by Alamar Blue assay, exposing various cell lines to the tested compounds for 4 days.